Immuno-Biological Laboratories Co., Ltd.
4570 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 藤岡市中字東田１０９１番地１
- Website:
- https://www.ibl-japan.co.jp/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Immuno-Biological Laboratories Co., Ltd. (IBL) is a prominent Japanese biotechnology company specializing in the development of innovative diagnostic tools and therapeutic solutions. With a strong focus on antibody production and lipoprotein analysis, IBL is renowned for its patented LipoSEARCH® technology, which utilizes advanced GP-HPLC systems for precise lipoprotein profiling. The company actively engages in cutting-edge research, contributing to scientific literature and clinical trials in various health fields, including cardiology and nephrology. IBL is committed to fostering collaborations, as evidenced by its partnerships with leading pharmaceutical firms. Through continuous innovation and a dedication to improving patient outcomes, IBL positions itself as a leader in the global biotechnology landscape.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-27 06:30 |
Inside Information Statement
臨時報告書
|
Japanese | 23.0 KB | |
| 2025-06-27 02:05 |
Internal Control over Financial Reporting
内部統制報告書－第43期(2024/04/01－2025/03/31)
|
Japanese | 25.4 KB | |
| 2025-06-27 02:04 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-06-27 02:02 |
Annual Report
有価証券報告書－第43期(2024/04/01－2025/03/31)
|
Japanese | 1.2 MB | |
| 2024-11-14 01:04 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-11-14 01:02 |
Interim Report
半期報告書－第43期(2024/04/01－2025/03/31)
|
Japanese | 180.6 KB | |
| 2024-06-26 03:44 |
Inside Information Statement
臨時報告書
|
Japanese | 23.0 KB | |
| 2024-06-26 03:41 |
Internal Control over Financial Reporting
内部統制報告書－第42期(2023/04/01－2024/03/31)
|
Japanese | 23.7 KB | |
| 2024-06-26 03:40 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-06-26 03:38 |
Annual Report
有価証券報告書－第42期(2023/04/01－2024/03/31)
|
Japanese | 1.2 MB | |
| 2024-02-14 01:10 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-02-14 01:07 |
Quarterly Report
四半期報告書－第42期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 161.4 KB | |
| 2023-11-14 01:02 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2023-11-14 01:01 |
Quarterly Report
四半期報告書－第42期第2四半期(2023/07/01－2023/09/30)
|
Japanese | 190.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
| TORII PHARMACEUTICAL CO., LTD. | Japan | 4551 | ||
|
TOWA PHARMACEUTICAL CO.,LTD. | Japan | 4553 | |
|
TSUMURA & CO. | Japan | 4540 | |
|
TURK İLAÇ VE SERUM SANAYİ A.Ş. | Türkiye | TRILC | |
|
UCB | Belgium | UCB | |
|
Valneva SE | France | VLA | |
|
VENTURE LIFE GROUP PLC | United Kingdom | VLG | |
|
Vetoquinol SA | France | VETO | |
|
Vicore Pharma Holding | Sweden | VICO | |
|
Vifor Pharma AG | Switzerland | VIFN |